BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26797240)

  • 21. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
    Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
    Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A critical appraisal of treatment for T3N0 colon cancer.
    Yo IS; Opelka FG; Bolton JS; Fuhrman GM
    Am Surg; 2001 Feb; 67(2):143-8. PubMed ID: 11243538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
    Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
    Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
    Ghosh P; Tie J; Muranyi A; Singh S; Brunhoeber P; Leith K; Bowermaster R; Liao Z; Zhu Y; LaFleur B; Tran B; Desai J; Jones I; Croxford M; Jover R; Goel A; Waring P; Hu S; Teichgraber V; Rohr UP; Ridder R; Shanmugam K; Gibbs P
    Clin Cancer Res; 2016 Jul; 22(14):3488-98. PubMed ID: 27029492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.
    Sinicrope FA
    Nat Rev Clin Oncol; 2010 Mar; 7(3):174-7. PubMed ID: 20190798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
    O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
    J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study.
    Oki E; Watanabe J; Sato T; Kagawa Y; Kuboki Y; Ikeda M; Ueno H; Kato T; Kusumoto T; Masuishi T; Yamaguchi K; Kanazawa A; Nishina T; Uetake H; Yamanaka T; Yoshino T
    ESMO Open; 2021 Jun; 6(3):100146. PubMed ID: 33984677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy for stage II colon cancer.
    Kopetz S; Freitas D; Calabrich AF; Hoff PM
    Oncology (Williston Park); 2008 Mar; 22(3):260-70; discussion 270, 273, 275. PubMed ID: 18494354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study.
    Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T
    J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.
    Loh KW; Michael M; Zalcberg JR; Jefford M
    Clin Colorectal Cancer; 2015 Sep; 14(3):192-7. PubMed ID: 26002619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
    Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
    Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
    Medinger M; Steinbild S; Mross K
    Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
    Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
    Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study.
    Kim KY; Cha IH; Ahn JB; Kim NK; Rha SY; Chung HC; Roh JK; Shin SJ
    J Surg Oncol; 2013 May; 107(6):613-8. PubMed ID: 23592499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
    Figueredo A; Germond C; Maroun J; Browman G; Walker-Dilks C; Wong S
    Cancer Prev Control; 1997 Dec; 1(5):379-92. PubMed ID: 9765760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.